Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

Table 1 Quality assessment by the cochrane collaboration’s tool

Reference	Random Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other bias
Borghaei, H. [34]	Unclear risk	Unclear risk	Unclear risk	Low risk	Low risk	Unclear risk	Unclear risk
Brahmer, J. [35]	Unclear risk	Unclear risk	Unclear risk	Unclear risk	Low risk	Unclear risk	Unclear risk
Carbone, D. P. [36]	Unclear risk	Unclear risk	Unclear risk	Low risk	Low risk	Unclear risk	Unclear risk
Hellmann, M. D. [33]	Unclear risk	Unclear risk	Unclear risk	Low risk	Unclear risk	Unclear risk	Unclear risk
Wu, Y. L. [38]	Low risk	Unclear risk	Unclear risk	Unclear risk	Unclear risk	Unclear risk	Unclear risk
Hellmann, M. D [39]	Low risk	Unclear risk	Unclear risk	Unclear risk	Unclear risk	Unclear risk	Unclear risk
Bazhenova, L [40]	Unclear risk	Unclear risk	Unclear risk	Unclear risk	Unclear risk	Unclear risk	Unclear risk

ISSN: 1475-2867